The 1922 Rand Revolt: white workers’ Marikana?

ASC – Publicaties niet-programma gebonde

Revisiting white labourism: new debates on working-class whiteness in twentieth-century Southern Africa

This article is a contribution to and reassessment of the debate about the concept of ‘white labourism’ hosted in this journal in 2010. White labourism is a concept formulated by Jonathan Hyslop to describe an ideology combining an anti-capitalist critique with racial segregation that he argued was dominant in a transnational white working class in the British Empire in the early twentieth century. The debate about this concept has focused on the appeal and extent of this ideology in South Africa during the early twentieth century. In light of recent scholarship on Southern Africa, we take a longer-term perspective to critically examine the concept and the debate. Specifically, we make three interventions into this debate: we consider the role of white workers outside British imperial networks; we examine how radical and revolutionary ideas disappeared from white-working class politics in the mid-twentieth century; and we reassess the connection between transnational flows of people and ideas. Racial divisions in the working class and labour movement in Southern Africa were persistent and enduring. We argue that racial segregation had an enduring appeal to white workers in Southern Africa, and the sources of this appeal were more varied and locally rooted than simply transnational migration to the region.ASC – Publicaties niet-programma gebonde

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Rethinking white societies in southern Africa: 1930s–1990s

This book showcases new research by emerging and established scholars on white workers and the white poor in Southern Africa. Rethinking White Societies in Southern Africa challenges the geographical and chronological limitations of existing scholarship by presenting case studies from Angola, Mozambique, South Africa, Zambia and Zimbabwe that track the fortunes of nonhegemonic whites during the era of white minority rule. Arguing against prevalent understandings of white society as uniformly wealthy or culturally homogeneous during this period, it demonstrates that social class remained a salient element throughout the twentieth century, how Southern Africa’s white societies were often divided and riven with tension and how the resulting social, political and economic complexities animated white minority regimes in the region. Addressing themes such as the class-based disruption of racial norms and practices, state surveillance and interventions – and their failures – towards nonhegemonic whites, and the opportunities and limitations of physical and social mobility, the book mounts a forceful argument for the regional consideration of white societies in this historical context. Centrally, it extends the path-breaking insights emanating from scholarship on racialized class identities from North America to the African context to argue that race and class cannot be considered independently in Southern Africa.bookASC – Publicaties niet-programma gebonde

Examining African contributions to global health: reflections on knowledge circulation and innovation

This article unites different disciplinary debates on 'southern innovation', 'theory from the South', and 'decolonisation of knowledge' in order to discuss existing understandings around the role of Africa in the production of health-related knowledge, public health policy, and medical innovation. Arguing that high-income countries have much to learn from the global South when it comes to health-related knowledge and practices, we propose an interdisciplinary research approach to uncovering and examining African contributions to global health, drawing on an ongoing collaborative project funded by the Swiss National Science Foundation. We present four empirical case studies concerning drug development, healthcare systems, and urban planning to critically enquire into both historical and contemporary transcontinental knowledge circulation and learning potentials, as much as cases of forgetting and silencing. On this basis, we argue that 'learning from the South' must mean more than transplanting quick and cheap technological fixes to serve societies in the global North, but rather recognising the vast contributions that Africans have made to global epistemologies, without losing sight of the asymmetries inherent in South-North knowledge exchanges. Lessons learned might apply to fields other than those discussed here and go far beyond 'reverse innovation'

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. RESULTS: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. CONCLUSION: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk